Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of IOP Injection for MRI Contrast in Healthy Subjects
NCT02744248Phase 1Completed
- Sponsor
- MegaPro Biomedical
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in liver neoplasms comparing IOP Injection with Placebo (2 arms). Primary endpoints: Dose limiting toxicities at 14 days and Maximum tolerated dose at 14 days. Started Feb 2016; status: completed.
02
Drugs
MPB-1514
03
Conditions
liver neoplasms
Beyond the preview
Go deeper on NCT02744248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744248.